Search

Your search keyword '"E. Bannò"' showing total 9 results
Start Over Author "E. Bannò"
9 results on '"E. Bannò"'

1. Estrogen receptor mutation: a new strategy to overcome endocrine resistance

Author

I. Toma, Antonio Frassoldati, A. Moretti, Christian Bassi, P. Querzoli, I. Carandina, C. Nisi, Laura Lupini, Massimo Negrini, F. Lancia, L. Da Ros, E. Bannò, F. Daniel, Lorenzo Belluomini, and L.R. Martella

Subjects
Genetics, medicine.medical_specialty, business.industry, Endocrine resistance, Hematology, NO, Endocrinology, Breast cancer, Oncology, Internal medicine, Mutation (genetic algorithm), medicine, business, Receptor
Published
2017

2. The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experience

Author

Antonio Frassoldati, F. Lancia, G. Mentrasti, F. Daniel, A. Moretti, I. Carandina, L.R. Martella, Lorenzo Belluomini, E. Bannò, M. Marzola, and I. Toma

Subjects
Oncology, 030213 general clinical medicine, medicine.medical_specialty, Focus (computing), Colorectal cancer, business.industry, Hematology, medicine.disease, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, chemistry, 030220 oncology & carcinogenesis, Internal medicine, Regorafenib, medicine, business
Published
2017

3. Efficacy and safety of immune checkpoint inhibitor nivolumab and radiotherapy combination in advanced NSCLC

Author

F. Lancia, F. Daniel, L.R. Martella, Antonio Frassoldati, Benedetta Urbini, A. Santini, Lorenzo Belluomini, Stefanelli A, I. Toma, Carlo Alberto Giorgi, E. Bannò, A. Moretti, and Fiorica F

Subjects
Oncology, Radiation therapy, medicine.medical_specialty, business.industry, Immune checkpoint inhibitors, medicine.medical_treatment, Internal medicine, medicine, Hematology, Nivolumab, business
Published
2017

4. Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: a systematic review and metanalysis

Author

Francesco Bonetti, Lorenzo Belluomini, F. Lancia, L.R. Martella, L. Da Ros, A. Moretti, F. Daniel, I. Toma, Benedetta Urbini, C. Nisi, E. Bannò, I. Carandina, and Antonio Frassoldati

Subjects
Oncology, medicine.medical_specialty, Chemotherapy, biology, Colorectal cancer, business.industry, medicine.medical_treatment, Wild type, Hematology, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, 030228 respiratory system, Internal medicine, medicine, biology.protein, 030212 general & internal medicine, Antibody, business
Published
2017

5. TILs evaluation in early stages of NSCLC

Author

C. Nisi, A. Moretti, Antonio Frassoldati, I. Carandina, G. Priante, E. Bannò, and R. Rinaldi

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Hematology, business
Published
2016

6. Multidisciplinary management in ovarian cancer

Author

G. Bernardi, I. Toma, A. Moretti, R. Martinello, F. Daniel, C. Nisi, F. Lancia, L. Da Ros, Lorenzo Belluomini, C. Borghi, E. Bannò, M. Marzola, L.R. Martella, and Antonio Frassoldati

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Medicine, Cancer, Ovarian tissue cryopreservation, Hematology, business, medicine.disease, Ovarian cancer
Published
2016

7. Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities?

Author

I. Toma, I. Carandina, F. Daniel, F. Lancia, E. Bannò, M. Marzola, Antonio Frassoldati, A. Moretti, L.R. Martella, M. Fabbri, and Lorenzo Belluomini

Subjects
medicine.medical_specialty, LS7_10, business.industry, Socio-culturale, Hematology, Gastroenterology, Irinotecan, Oncology, Internal medicine, Genotype, Medicine, Dose reduction, business, medicine.drug
Published
2016

Catalog

Books, media, physical & digital resources
See catalog results